158 related articles for article (PubMed ID: 11906550)
41. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
42. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
43. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
Lydiksen L; Jensen-Fangel S; Blaakaer J
Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
[TBL] [Abstract][Full Text] [Related]
44. [Neoadjuvant chemotherapy and ovarian cancer].
Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
[TBL] [Abstract][Full Text] [Related]
45. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma.
Kuhn W; Rutke S; Späthe K; Schmalfeldt B; Florack G; von Hundelshausen B; Pachyn D; Ulm K; Graeff H
Cancer; 2001 Nov; 92(10):2585-91. PubMed ID: 11745193
[TBL] [Abstract][Full Text] [Related]
46. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients.
Vergote I; De Wever I; Tjalma W; Van Gramberen M; Decloedt J; van Dam P
Gynecol Oncol; 1998 Dec; 71(3):431-6. PubMed ID: 9887245
[TBL] [Abstract][Full Text] [Related]
48. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking.
Le T; Shahriari P; Hopkins L; Faught W; Fung Kee Fung M
Int J Gynecol Cancer; 2006; 16(3):986-90. PubMed ID: 16803473
[TBL] [Abstract][Full Text] [Related]
50. Primary epithelial ovarian carcinoma in Taiwanese women.
Wang PH; Yuan CC; Juang CM; Lai CR; Yen MS; Chao HT; Ng HT
Eur J Gynaecol Oncol; 2001; 22(1):57-60. PubMed ID: 11321496
[TBL] [Abstract][Full Text] [Related]
51. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study.
Vrscaj MU; Rakar S
Eur J Gynaecol Oncol; 2002; 23(5):405-10. PubMed ID: 12440812
[TBL] [Abstract][Full Text] [Related]
52. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study.
Sabatier R; Calderon B; Lambaudie E; Chereau E; Provansal M; Cappiello MA; Viens P; Rousseau F
Int J Gynecol Cancer; 2015 Jun; 25(5):815-22. PubMed ID: 25768081
[TBL] [Abstract][Full Text] [Related]
54. Only complete tumour resection after neoadjuvant chemotherapy offers benefit over suboptimal debulking in advanced ovarian cancer.
Vermeulen CKM; Tadesse W; Timmermans M; Kruitwagen RFPM; Walsh T
Eur J Obstet Gynecol Reprod Biol; 2017 Dec; 219():100-105. PubMed ID: 29078115
[TBL] [Abstract][Full Text] [Related]
55. Impact of Preoperative Serum Levels of CA 125 on Epithelial Ovarian Cancer Survival.
Pradjatmo H; Pradjatmo H
Asian Pac J Cancer Prev; 2016; 17(4):1881-6. PubMed ID: 27221870
[TBL] [Abstract][Full Text] [Related]
56. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
57. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy.
Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E
Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273
[TBL] [Abstract][Full Text] [Related]
58. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
59. Prognostic analysis of ovarian cancer associated with endometriosis.
Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
[TBL] [Abstract][Full Text] [Related]
60. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]